Company Profile
Catalyst Biosciences Stock Price, News & Analysis
Company overview
Business overview
Catalyst Biosciences is a biopharmaceutical company focused on pipeline execution and catalyst-driven growth, with investors tracking how data, regulatory milestones, and launch timing reshape the investment case.
Geographic Base and Sector Classification
Headquartered in the United States and listed on NASDAQ, Catalyst Biosciences is followed within the biopharmaceutical universe for its exposure to pipeline and commercialization catalysts.
Business Model Characteristics
Catalyst Biosciences follows a pipeline-led model where clinical readouts, filing updates, and program expansion determine how the market underwrites the story.
Position Within the Biotechnology Landscape
Compared with more mature healthcare names, Catalyst Biosciences sits on the development side of the biotech landscape, where catalyst timing can reprice the stock quickly.
Why the stock is moving
CBIO is trading with a steady catalyst profile while investors wait for the next headline that changes the story.
Future catalysts
Catalyst Biosciences is largely a legacy / closeout story, with catalysts limited to any remaining strategic update. There is no active standalone growth story left.
Recent news
The five most recent feed items are shown below in reverse chronological order.
- 01
- 02
Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business Update
Source: Catalyst Biosciences
- 03
Gyre Therapeutics Announces the Appointment of Dan Weng, M.D., to Board of Directors
Source: Catalyst Biosciences
- 04
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Source: Catalyst Biosciences
- 05
Similar stocks
Peer names with similar commercial maturity, therapeutic overlap, or catalyst patterns.